Clinical data | |
---|---|
Trade names | Many[1] |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intramuscular[2] Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.189.847 |
Chemical and physical data | |
Formula | C16H26O5 |
Molar mass | 298.379 g·mol−1 |
3D model (JSmol) | |
Melting point | 86 to 88 °C (187 to 190 °F) |
| |
| |
(what is this?) (verify) |
Artemether is a medication used for the treatment of malaria.[1][2] The injectable form is specifically used for severe malaria rather than quinine.[2] In adults, it may not be as effective as artesunate.[2] It is given by injection in a muscle.[2] It is also available by mouth in combination with lumefantrine, known as artemether/lumefantrine.[1][3]
Artemether causes relatively few side effects.[4] An irregular heartbeat may rarely occur.[4] While there is evidence that use during pregnancy may be harmful in animals, there is no evidence of concern in humans.[4] The World Health Organization (WHO) therefore recommends its use during pregnancy.[4] It is in the artemisinin class of medication.[4]
Artemether has been studied since at least 1981, and has been in medical use since 1987.[5] It is on the World Health Organization's List of Essential Medicines.[6]
Coartem FDA label
was invoked but never defined (see the help page).